Recent news on

Somaxon Pharmaceuticals Reports 2006 Second Quarter Financial ...  Aug 9, 2006
Operating expenses grew as expected and were primarily due to the company's ongoing Phase 3 clinical trials for SILENOR(TM) (doxepin hydrochloride), Phase 2/3 ... -Yahoo! News

Somaxon Pharmaceuticals Reports 2006 Second Quarter Financial ...  Aug 9, 2006
Operating expenses grew as expected and were primarily due to the company’s ongoing Phase 3 clinical trials for SILENOR™ (doxepin hydrochloride), Phase 2/3 ... -WebWire

Somaxon Pharmaceuticals to Report 2006 Second Quarter Financial ...  Jul 18, 2006
Somaxon's lead product candidate, SILENOR(TM) (doxepin hydrochloride), is in Phase 3 clinical trials for the treatment of insomnia. ... -Drug Newswire



Somaxon Pharmaceuticals Names Matthew Onaitis Vice President of ...  16 May 2006
Somaxon's lead product candidate, SILENOR(TM) (doxepin hydrochloride), is in Phase 3 clinical trials for the treatment of insomnia. ... - PR Newswire

Somaxon Pharmaceuticals Reports 2006 First Quarter Financial ...  May 10, 2006
...progress in its drug development programs, including completion of the first Phase 3 clinical trial for SILENOR(TM) (doxepin hydrochloride), its lead product ... - Yahoo! News





Somaxon Pharmaceuticals Announces Positive Phase 3 Results with ...  Apr 10, 2006
SILENOR(TM) is a low-dose (1 mg, 3 mg, 6 mg) oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. ... - Yahoo! News

Somaxon Pharmaceuticals, Inc. to Present at the 18th Annual Roth ...  Feb 15, 2006
Somaxon's lead product, SILENOR(TM) (doxepin hydrochloride) 1mg, 3mg, 6mg, is in Phase III clinical trials for the treatment of insomnia. - PharmaLive.com,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional